ASX:AHZ

Stock Analysis Report

Executive Summary

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices.


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Admedus's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AHZ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

20.8%

AHZ

12.6%

AU Medical Equipment

7.1%

AU Market


1 Year Return

-18.7%

AHZ

8.8%

AU Medical Equipment

-19.4%

AU Market

Return vs Industry: AHZ underperformed the Australian Medical Equipment industry which returned 9.1% over the past year.

Return vs Market: AHZ matched the Australian Market which returned -18.8% over the past year.


Shareholder returns

AHZIndustryMarket
7 Day20.8%12.6%7.1%
30 Day-27.9%-13.0%-21.3%
90 Day-55.3%-16.1%-24.8%
1 Year-18.7%-18.7%10.8%8.8%-15.8%-19.4%
3 Year-86.5%-86.5%31.7%25.5%-2.4%-15.8%
5 Year-93.8%-93.8%70.6%55.8%8.4%-16.0%

Price Volatility Vs. Market

How volatile is Admedus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Admedus undervalued compared to its fair value and its price relative to the market?

1.7x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AHZ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AHZ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AHZ is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: AHZ is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AHZ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AHZ is good value based on its PB Ratio (1.7x) compared to the AU Medical Equipment industry average (3.4x).


Next Steps

Future Growth

How is Admedus forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Admedus has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Admedus performed over the past 5 years?

6.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AHZ is currently unprofitable.

Growing Profit Margin: AHZ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AHZ is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.

Accelerating Growth: Unable to compare AHZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AHZ is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: AHZ has a negative Return on Equity (-39.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Admedus's financial position?


Financial Position Analysis

Short Term Liabilities: AHZ's short term assets (A$20.6M) exceed its short term liabilities (A$7.3M).

Long Term Liabilities: AHZ's short term assets (A$20.6M) exceed its long term liabilities (A$3.2M).


Debt to Equity History and Analysis

Debt Level: AHZ's debt to equity ratio (7.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AHZ's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: AHZ has a low level of unsold assets or inventory.

Debt Coverage by Assets: AHZ's debt is covered by short term assets (assets are 18.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AHZ has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AHZ has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.2% each year


Next Steps

Dividend

What is Admedus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AHZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AHZ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AHZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AHZ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AHZ's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Wayne Paterson (52yo)

3.83s

Tenure

AU$1,901,097

Compensation

Mr. Wayne G. Paterson is the Founder and Chief Executive Officer of ProCom Rx since June 2013. Mr. Paterson has been Chief Executive Officer of Admedus Limited since March 15, 2017 and serves as its Managi ...


CEO Compensation Analysis

Compensation vs Market: Wayne's total compensation ($USD1.17M) is above average for companies of similar size in the Australian market ($USD245.57K).

Compensation vs Earnings: Wayne's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Wayne Paterson
CEO, President3.83yrsAU$1.90m0.16% A$39.9k
Matthew McDonnell
Chief Financial Officer1.25yrsAU$629.63kno data
David Denis
Chief Operating Officer2.67yrsAU$944.42kno data
Martha Engel
General Counsel1yrAU$402.52kno data
Kiran Bhirangi
Chief Medical Officer1.25yrsAU$693.96kno data
Stephen Denaro
Independent Non-Executive Director & Company Secretary1.42yrsAU$160.00kno data
Chris Olig
Business Development and Portfolio Planning Director3.42yrsno datano data
Danny Zanardo
Commercial Director of Internationalno datano datano data
Ian Frazer
Executiveno datano datano data

1.4yrs

Average Tenure

Experienced Management: AHZ's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Wayne Paterson
CEO, President3.83yrsAU$1.90m0.16% A$39.9k
Stephen Denaro
Independent Non-Executive Director & Company Secretary1.42yrsAU$160.00kno data
John Seaberg
Independent Chairman of the Board3yrsAU$201.32k0.15% A$38.5k
Wenyi Gu
Non-Executive Director1.42yrsAU$110.00kno data
Yanheng Wu
Non-Executive Director1.25yrsno datano data

1.4yrs

Average Tenure

Experienced Board: AHZ's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 93.2%.


Top Shareholders

Company Information

Admedus Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Admedus Limited
  • Ticker: AHZ
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$25.702m
  • Shares outstanding: 5.91m
  • Website: https://www.admedus.com

Location

  • Admedus Limited
  • Toowong Tower
  • Suite 302
  • Toowong
  • Queensland
  • 4066
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AHZASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2011
AMEU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2011
DDFDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2011

Biography

Admedus Limited, a healthcare company, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company offers CardioCel, a bio-scaffold material to repair congenital heart deformities and other heart defects, as well as to reconstruct dysfunctional heart valves and valve leaflets; and CardioCel 3D that enables physicians access to an arch reconstruction solution with non-antigenic response and calcification resistance. It also provides VascuCel, a collagen scaffold used in cardiac repairs and reconstructions; ambIT infusion pumps for the delivery of medications and pain relief; arcomed infusion systems; and Eldor, a specialized fenestrated catheters for the infusion of local anesthetics into surgical sites for post-operative pain management. In addition, the company offers DOSI-FUSER, a portable elastomeric pump; and DOSI-PAIN, a wound catheter for postoperative continuous infusion. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 10:38
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.